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Abstract 
Despite the many advances in the treatment of hematological malignancies over the past 
decade, outcomes in refractory lymphomas remain poor.  One potential strategy in this 
patient population is the specific targeting of IL-2R-α (CD25), which is over-expressed on 
many lymphoma and leukemic cells, using antibody drug conjugates (ADCs). ADCT-301 is 
an ADC composed of human IgG1 HuMax®-TAC against CD25, stochastically conjugated 
through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a 
drug-antibody ratio (DAR) of 2.3. ADCT-301 binds human CD25 with picomolar affinity. 
ADCT-301 has highly potent and selective cytotoxicity against a panel of CD25-expressing 
human lymphoma cell lines. Once internalized, the released warhead binds in the DNA 
minor groove and exerts its potent cytotoxic action via the formation of DNA interstrand 
cross-links. A strong correlation between loss of viability and DNA cross-link formation is 
demonstrated. DNA damage persists, resulting in phosphorylation of histone H2AX, cell 
cycle arrest in G2/M and apoptosis. Bystander killing of CD25-negative cells by ADCT-301 is 
also observed. In vivo, a single-dose of ADCT-301 results in dose-dependent and targeted 
antitumor activity against both subcutaneous and disseminated CD25-positive lymphoma 
models. In xenografts of Karpas 299, which expressed both CD25 and CD30, marked 
superiority over brentuximab vedotin (Adcetris®) is observed. Dose-dependent increases in 
DNA cross-linking, γ-H2AX and PBD payload staining were observed in tumors in vivo 
indicating a role as relevant pharmacodynamic assays. Together these data support the 
clinical testing of this novel ADC in patients with CD25-expressing tumors.  
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Introduction 
In 2015 in the United States there were an estimated 80,900 and 54,270 new diagnoses of 
all-type lymphoma and leukemia, and 20,490 and 24,450 deaths, respectively.(1) Both 
Hodgkin’s lymphoma (HL) and various T and B-cell Non-Hodgkin’s lymphoma (NHL) tumor 
cells express IL-2R-α (CD25).(2, 3) At least two leukemic diseases, Adult T-cell leukemia 
lymphoma (ATLL)(4) and hairy cell leukemia(5), show near 100% expression of CD25 on 
their circulating tumor cells. In the refractory setting there is evidence of maintenance of 
CD25 expression, and in acute myeloid leukemia (AML), its upregulation.(6) Although not 
unique to hematological malignancy, increased CD25 expression can be detected via 
shedding of this receptor.(7, 8) Indeed, high soluble IL-2R-α serum levels have helped 
identify patients with poorer prognoses in diffuse large B-cell lymphoma, cutaneous 
lymphomas, follicular lymphoma, AML, acute lymphoblastic leukemia, Hodgkin’s 
lymphoma(9-14) and are used as part of a prognostic index in ATLL.(15)  
 
A number of clinical trials have, demonstrated the utility of targeting this receptor in 
oncology. Phase I clinical trials of three radioimmunoconjugates, 90Yttrium-labeled anti-
Tac(16),131Iodine-labeled basiliximab(17) and 90Yttrium-labeled daclizumab(18) have 
demonstrated complete responses in patients with CD25-expressing lymphomas. The 
delayed myelosuppression seen with each of these anti-CD25 radionuclides was thought to 
be due to each β-emitting radionuclide having an effect on red marrow rather than an anti-
CD25 antibody specific effect (16-18). Two anti-CD25 immunotoxin conjugates have been 
tested in a number of human trials. LMB-2, a pseudomonal exotoxin conjugated to an anti-
CD25 single chain variable fragment (19) has shown objective responses in CD25-
expressing lymphomas including ATLL(20) and denileukin-diftitox (Ontak™), a diphtheria 
exotoxin conjugated to an IL-2 fragment(21) is licensed in CD25-positive cutaneous T cell 
lymphoma. Despite immunogenicity and manufacturing obstacles (22), immunotoxins remain 
a promising field of targeted therapies. (23) Anti-CD25 radioimmunoconjugates and 
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immunotoxins have both provided proof of concept for the feasibility of targeting the CD25 
receptor with few toxicity concerns and have provided a platform for the preclinical 
development of new anti-CD25 targeting drugs. 
 
The development of ADCs, however, has arguably been the immunoconjugate class most 
propelled by the commercial successes of therapeutic monoclonal antibody technologies. 
(24) This is at least partly because the synthesis of purified ADCs can now be carried out in 
a controlled way using optimised linker technologies. (24) The use of antibody drug 
conjugates (ADCs) in oncology indications has risen to prominence in the past decade, 
highlighted by FDA licensing of Adcetris in 2011 and trastuzumab emtansine (Kadcyla ®) in 
2013.(24) More recently novel ADCs delivering pyrrolobenzodiazepine (PBD) dimers as the 
cytotoxic warhead have been developed. PBD dimers are a class of exquisitely-potent DNA 
minor groove interstrand cross-linking agents, one of which, SG2000 (SJG-136), has shown 
activity against both solid tumors and hematological malignancies.(25, 26) Advantages over 
ADCs targeting other warheads including tubulin inhibitors (e.g. auristatins and 
maytansinoids), DNA damaging drugs (e.g. calicheamicin) and classical chemotherapeutics 
include the ability to target low copy number antigens, and to exploit low drug antibody ratios 
(DARs). Due to their novel mechanism of action, PBD-containing ADCs are active in tumors 
inherently resistant to other warhead types and against multidrug resistant tumors.(27) 
 
Here we report the characterization, mechanism of action and preclinical evaluation of a 
novel anti-CD25 ADC, ADCT-301. 
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Materials and methods 
Synthesis of ADCT-301 
HuMax-TAC antibody was first buffer exchanged into a proprietary histidine buffer at pH 6 
containing various carbohydrate-based stabilising additives using tangential flow filtration 
(TFF) on Pellicon 30kDa cassettes using 10 diavolumes at constant TMP of 1.0 bar. 
Antibody was concentrated to ca. 10 mg/ml and the pH was adjusted to 7.5 using a 
TRIS/EDTA ph 8.5 buffer. 10mM TCEP reductant was added to the batch as a 1.25 excess 
with respect to HuMax-TAC mAb and the reduction reaction was allowed to proceed for 60 
min at 20˚C. Dimethylacetamide (DMA) and 10 mM SG3249 (28) were added to the solution 
to a final 5% DMA v/v and three-fold excess relative to antibody.  The conjugation reaction 
was incubated at 20 ˚C for 60 min, then quenched with three-fold molar excess of N-Acetyl 
cysteine and incubated at 20˚C for 20 min. The pH was then decreased to 6.0 using histidine 
hydrochloride solution and the ADC purified by TFF using the same conditions as the first 
buffer exchange step, this time with 12 diavolumes of the histidine/carbohydrate additive 
buffer. The solution was filtered (0.22 μm) and stored at -70°C.  Final yield was estimated 
from starting antibody by UV/Vis. 
 
Human cell lines 
The anaplastic large cell lymphoma (ALCL) cell lines Karpas 299 (2012) and Su-DHL-1 
(2012) and the Hodgkin’s lymphoma (HL) cell lines L-540 (2014) and HDLM-2 (2014) were 
obtained from the Deutsche Sammlung von Mikroorganismen und Zellkuturen (DSMZ) 
(Braunschweig, Germany). The Burkitt lymphoma cell lines Daudi (2012) and Ramos (2012) 
and the cutaneous T-cell lymphoma line HuT-78 (2013) were obtained from the American 
Type Culture Collection (ATCC) supplier LGC Standards (Middlesex, UK). The myeloid 
leukemia cell lines, EoL-1 and KG-1 were obtained from DSMZ and LGC Standards, 
respectively (2015). Characterization of these mycoplasma negative cell lines was 
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performed by the cell bank supplier and included the determination and the verification of 
tissue-specific antibodies, karyotyping and expression of aberrantly expressed genes. As 
cell lines were passaged for fewer than 6 months after receipt or resuscitation, they were not 
authenticated or tested in our laboratory. Cells were cultured in RPMI-1640 media (Sigma-
Aldrich, Dorset, UK) or IMDM (LGC Standards) with added L-glutamine (Sigma-Aldrich) or in 
L-glutamine-containing media (LifeTech, Paisley, UK) each of which was supplemented with 
heat-inactivated fetal bovine serum (FBS) as per the supplier’s instructions. 
In vitro binding and internalization assays 
Binding of HuMax-TAC or ADCT-301 to cell lines was detected with an Alexa Fluor 488 
(AF488)-labeled anti-human IgG (LifeTech). For internalization studies, Karpas 299 cells 
were exposed (1h at 4°C) to ADCT-301 in blocking buffer (PBS, 10% (v/v) normal goat 
serum, 0.1% sodium azide (w/v)). Cells were washed and incubated for various periods in 
medium over a time course at 37°C after which time they were centrifuged, washed and 
fixed (neutral buffered formalin). Once all time points were collected, plates were centrifuged 
(400 g), washed and incubated with either a saturating antibody concentration of mouse 
IgG1 CD25 antibody (BD Biosciences) or a mouse non-targeted (isotype control) monoclonal 
antibody MOPC (BD Biosciences), in blocking buffer for 1h at 4°C. The potential for 
competition of binding to the same IL-2R-α epitope by ADCT-301 and mouse anti-human 
CD25 was measured in a competition assay by co-incubation of cells with increasing 
concentrations of ADCT-301 and a saturating concentration of mouse anti-human CD25. 
After washing and re-suspension, the Qifikit protocol(29) (DAKO, Cambridge, UK) was 
followed, labeling cells with an anti-mouse FITC-labeled antibody (DAKO). For 
immunofluorescent imaging of ADCT-301 treated CD25-positive cell lines, cells were fixed 
(4% paraformaldehyde) at each time point, re-suspended in permeabilization/wash buffer 
(BD Biosciences) and then incubated with APC-labeled mouse anti-human LAMP-1 (BD 
Biosciences) and AF488-labeled anti-human antibody (LifeTech), while nuclear 
counterstaining was performed with Hoechst 33342 (LifeTech) (1h at 4°C). After cell 
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cytospins were generated, slides were mounted with prolong gold antifade (LifeTech) and 
slide edges sealed with clear nail polish. Images from dried slides kept at 4°C were captured 
on a TCS SPE confocal system utilizing a DM2500 microscope (Leica) (40x or 63x oil 
immersion objective) using three solid state excitation lasers (405, 488 and 635 nm). 
Alternatively, Karpas 299 cells were incubated with ADCT-301, washed, and then either kept 
at 4°C in PBS, 0.1% azide or re-suspended in medium and incubated at 37°C over a time 
course to 4h. After each time point, cells were washed and incubated with an AF488-labeled 
anti-human IgG (1h at 4°C).  After washing and re-suspension of all labeled cells in PBS, 
0.1% sodium azide, cells were analyzed on an Accuri, C6 flow cytometer (BD Biosciences, 
Oxford, UK). Median fluorescent intensity (MFI) of the live cell population was determined 
using Flowjo 7.0 (Tree Star Inc., Ashland, OR). GraphPad (San Diego, CA) was used to 
calculate an EC50 or a linear regression model for calculating CD25 molecule numbers per 
cell. The Qifikit protocol(29) was also used to determine CD30 copy number with a mouse 
IgG1 CD30 antibody (GeneTex, Nottingham, UK). 
Surface plasmon resonance 
Human soluble CD25-streptavidin fusion protein transiently produced in CHO cells (Evitria, 
Zurich, Switzerland) was immobilised by amine coupling to a Biacore CM3 sensor chip (GE 
Healthcare, Little Chalfont, UK). A concentration range (0.05 to 5 nM) of HuMax-TAC and 
ADCT-301 was injected over the chip for 120 seconds as per the Biacore multi-cycle kinetics 
method and allowed to dissociate by running HBS-EP buffer (Hepes-buffered saline 
containing EDTA and surfactant P20) over the chip for 60min. The equilibrium dissociation 
constant KD was calculated with Biaevaluation software (GE). 
Cell survival determination by MTS assay 
Cell viability was measured following either 96h incubation at 37°C to ADC, non-binding 
ADC or warhead dilution series, or a 2h exposure and wash, followed by further 94h 
incubation. For the measurement of bystander killing, Karpas 299 cells were incubated with 
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serial dilutions of ADCT-301 or non-binding ADC in 96-well round-bottom plates for 48h. 
Centrifuged Karpas 299 conditioned medium (50 µl) was added to 50 µl of Ramos cell 
culture in 96-well flat-bottom plates and incubated for 96h. For all experiments cell survival 
was determined by absorbance measurements on a Varioskan™ Flash Multimode Reader 
(Thermo Fisher Scientific, Hempstead, UK) according to a standard MTS protocol.(30) 
Percentage growth inhibition was calculated from the mean absorbance in the triplicate 
ADC-treated wells, compared to the mean absorbance in the control wells (100 %). Dose-
response curves were generated from the mean data of each independent experiment. The 
GI50 was determined by fitting a sigmoidal dose response curve to the data using Graphpad. 
Co-culture and viability flow cytometry assays  
Unlabeled Karpas 299 cells and PKH-26-labeled (Sigma-Aldrich, UK) Ramos cells (20 µM) 
were diluted (1.5 x 105 cells/ml) in medium and dispensed into round-bottom, ultralow-
attachment 96-well microplates (Corning) as follows: mono-culture: 50 µl cells plus 50 µl 
growth medium; co-cultures: 50µl Karpas 299 plus 50 µl labeled Ramos.  Serial dilutions of 
ADCT-301 and non-binding ADC, containing 20 µM TGF-β inhibitor, SB431542 (Sigma-
Aldrich) were added (100µl/well) to single and co-cultures.  Cells were mixed on an IKA 
Vibrax shaker (10sec) and incubated at 37°C for 96h. After washing and re-suspension in 
PBS, Fixable Dead Cell Stain (LifeTech) was added. Cells were re-suspended and 
incubated in the dark for 30 min.  Alternatively, in apoptosis experiments, Karpas 299 cells 
(1.5 x 105/ml) were dispensed with ADCT-301 or non-binding ADC as described above. 
Etoposide was used as a positive apoptosis control. Cells were incubated at 37°C over a 
time course. At each time point, cells were centrifuged, washed, re-suspended in Fixable 
Dead Cell Stain and FITC-labeled Annexin-V antibody (BD Biosciences) diluted in Annexin-V 
Calcium free buffer and incubated for 30min (RT). Annexin-V buffer (250µl) was added to 
each well before analysis on an Accuri C6 flow cytometer. Data were analyzed in FlowJo. 
Total, live and dead cell counts from three replicate experiments were obtained from 
quadrant plots after compensation was carried out as necessary. Counts were normalised to 
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the total cell count per well for each condition, to reflect the percentage of cells that 
remained viable or were apoptosed.  
In vitro and in vivo cross-linking determination by single cell gel electrophoresis 
(comet) assay 
Cell lines were incubated with ADCT-301 or non-binding ADC (20 ng/ml) for 2h at 37°C, 
washed, re-suspended in medium and incubated at 37°C over a further time course (2 - 
36h). After each time point, cells were centrifuged, re-suspended in freezing medium (FBS 
with 10% DMSO) and frozen at -80°C. An equimolar concentration of SG3199 was 
dispensed into cell suspension, incubated for two hours and the same procedure for 
harvesting ADC-exposed cells followed. To determine percentage cross-linking of increasing 
doses of ADCT-301 or non-binding ADC on expressing cell lines each ADC dilution was 
added to cells for two hours at 37°C. Cells were washed, re-suspended in culture medium, 
dispensed into 24 well plates, incubated for 24h at 37°C and harvested, as above. For 
analysis of cross-linking on Karpas 299 subcutaneously implanted into SCID mice, cell 
suspensions were prepared from the excised tumors removed 24h after dosing with 0.2 or 
0.6 mg/kg ADCT-301 or left untreated and stored in freezing medium at -80°C. Peripheral 
blood mononuclear cells (PBMCs) from each mouse were isolated from whole blood using a 
Ficoll gradient and stored in freezing medium at -80°C. Frozen cells were thawed on ice, re-
suspended in cold RPMI (Sigma) and counted. Cell suspensions (2-3 x 104 cells/ml), 
excepting un-irradiated controls, were irradiated (15 Gy) and kept on ice. The Comet assay 
was performed as previously described.(31) Slides were reviewed under a 20x objective on 
an epi-fluorescence microscope equipped with: Hg arc lamp; 580 nm dichroic mirror; and 
535 nm excitation and 645 nm emission filters suitable for visualising propidium iodide 
staining with a minimum of 50 Comet images acquired per treatment condition. The Olive 
Tail Moment (OTM) was determined as the product of the tail length and the fraction of total 
DNA in the tail as recorded by Komet 6 software (Andor Technology, Belfast, UK) and the 
percentage reduction in OTM calculated according to the formula: 
10 
 
% decrease in tail moment = [1- (TMdi- TMcu)/(TMci – TMcu)] * 100 
TMdi= Tail Moment drug irradiated; TMcu= TM control un-irradiated; TMci = TM control irradiated 
Analysis was performed on Microsoft Excel and GraphPad. 
γ-H2AX foci quantification 
Karpas 299 cells treated with serial dilutions of ADCT-301 concentrations and frozen at -
80°C, were thawed, washed in PBS, fixed with 4% paraformaldehyde for 5min at room 
temperature and washed in PBS. Cell cytospins were generated for each treatment condition 
and cells were permeabilized with PBS/0.2% Triton-X100, washed in PBS and blocked in 
10% FBS, 5% BSA in PBS. After incubation overnight (4°C) with goat anti-mouse γ-H2AX 
(JBW301) (Millipore, UK) in 1% FBS in PBS, slides were washed and incubated (1h at RT) 
with AF488-labeled goat anti-mouse IgG antibody (LifeTech) then counterstained with 
Hoecsht 33342 (LifeTech). Slides were washed in PBS and distilled water, mounted with 
prolong gold antifade (LifeTech) and the coverslip edges sealed with clear nail polish. 
Images captured on a confocal system as described above, were compressed to a 
maximum intensity projection image of z-stack acquired images to allow maximal detection 
of foci and analyzed in Image J. Cell Profiler was used to quantify γ-H2AX foci per cell in at 
least 20 cells per treatment. 
Cell cycle analysis 
Karpas 299 cells were treated with ADCT-301, SG3199, non-binding ADC or left untreated. 
Ethanol fixed nuclei were stained with 0.5 mg/ml propidium iodide (PI) (Sigma) in the 
presence of 100 µg/ml RNAase (Sigma) (1h at 37°C). Cells were analyzed by flow cytometry 
(FACSVerse, BD Bioscience).  Histograms of the singlet live cell population in the PI 
emission spectrum were drawn using the cell cycle function in Flowjo and analyses of cell 
cycle percentages performed in GraphPad.  
 
11 
 
Assessment of ADCT-301 efficacy in subcutaneous in vivo models  
Karpas 299 xenografts were established in 6-8 week old female Fox Chase SCID® (C.B-
17/Icr-Prkdcscid, Charles River) by implanting 107 cells subcutaneously into their flanks. Su-
DHL-1 xenografts were established by injection of 107 cells (50% matrigel) into 10 week old 
nude mice (Nu (NCr)-Fox1nu, Charles River). When tumors reached approximately 100-155 
mm3 mice were randomly allocated into groups to receive ADCT-301, non-binding ADC, 
PBS (vehicle) or Adcetris intravenously. Clinical grade Adcetris was purchased from Seattle 
Genetics (Seattle, WA). Mice were in the body weight range of 15.5 to 27.6 g on Day 1 of the 
studies. Each animal was euthanized when its tumor reached the endpoint volume of 2,000 
mm3 or at study end. The time to endpoint (TTE) for analysis was calculated for each mouse 
by the following equation:  
TTE (days) = ([log 10 (endpoint volume– intercept*] / slope*) 
*of the line obtained by linear regression of a log-transformed tumor growth data set 
The logrank test was used to analyze the significance of differences between the TTE values 
of two groups. The setup of experimental procedures used in Karpas 299 and Ramos 
disseminated models are described in Supplemental Methods and Tables. 
Assessment of ADCT-301 pharmacokinetics and toxicity in non-tumor bearing SCID 
mice 
ADCT-301 was administered i.v. as a single dose (1-12 mg/kg) to non-tumor bearing CB.17 
SCID mice, following which mice were observed for weight changes and toxicities. 
Alternatively, to measure the pharmacokinetic profile of naked antibody, HuMax-Tac or 
ADCT-301, 1 mg/kg of each drug was administered i.v as a single dose to non-tumor 
bearing mice. Blood collection was performed at specified time points (25 μL of blood from 
mice tail veins diluted in 225 μL PBS in 6% EDTA). The samples were spun down at 400 g 
for 5 mins, the supernatant was aspirated and stored at -80°C and measurement of samples’ 
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total antibody and ADC (DAR ≥ 1) concentrations performed by an optimised ELISA assay.  
In order to measure antibody in each sample, Immuno MaxiSorp plates (Thermo Fisher 
Scientific) were first coated with sCD25‐Strepavidin (Evitria) in PBS and incubated overnight 
(4°C). Alternatively, to measure conjugated ADC, DAR >=1, identical plates were coated 
with anti‐PBD antibody in PBS and incubated overnight (4°C). Plates were then washed x 3 
(0.05% Tween) and blocked (3% BSA/PBS) for 1h. Reference, QC and test samples were 
prepared and added to polypropylene plates (Thermo Fisher Scientific) (2 h at RT). They 
were then washed x 3 and mouse anti‐human IgG1‐HRP conjugate (Sanquin) added and 
plates incubated for 1h (RT). Plates were washed x 3, Ultra TMB (Thermo Fisher Scientific) 
added and incubated for 10 min at RT. Stop solution of 1M HCL was added and absorbance 
was read at 450 nm on an Envision plate reader. In order to quantify absorbance, calibration 
curves were established in assay buffer (0.5xBlotto+0.05% Tween in PBS) containing 2.5% 
or 0.5% pooled mouse serum. The pharmacokinetic analysis of ADCT-301 and HuMax-TAC 
concentrations was performed using Phoenix WinNonlin Version 6.2 with non-
compartmental analysis.  
Animal care compliance 
The Institutional Animal Care and Use Program at Charles River Discovery Services are 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC), which assures compliance with accepted standards for the care and 
use of laboratory animals. 
Immunohistochemistry of tumor xenograft sections 
Murine xenograft tumors untreated or treated with 0.2 mg/kg or 0.6 mg/kg ADCT-301 were 
fixed in buffered formalin and embedded in paraffin according to a conventional protocol. 2-5 
µm sections were cut and transferred on electrically charged slides to be subjected to 
immunohistochemistry. Testing of an anti-SG3249 payload antibody (14B3-B7) (ADC 
Therapeutics, UK) and an antibody to detect phosphorylation of Histone H2A.X at position 
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Ser139 (New England Biolabs, Hitchin, UK) was carried out with staining conditions (i.e. 
antibody dilution, incubation time, and antigen retrieval method) optimized on ADCT-301-
treated or irradiated-Karpas 299 cytospins. Single immunostaining was performed using a 
BOND-III Autostainer (Leica Microsystems, UK) according to protocols described 
elsewhere.(32, 33) Stained slides were scanned with the NanoZoomer Digital Pathology 
System (Hamamatsu, Japan) and images reviewed with NDP viewer. 
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Results 
Properties of ADCT-301 
ADCT-301 is an ADC composed of HuMax®-TAC, a human IgG1 anti-CD25 antibody, 
maleimide-conjugated at reduced interchain cysteines via a cathepsin-cleavable valine-
alanine (val-ala) linker to PBD dimer warhead SG3199 (Figure 1A). The ADC was 97% 
monodisperse as determined by size-exclusion chromatography (Supplemental Figure S1A, 
Supplemental Table S1). Drug antibody ratio (DAR) was determined by reverse-phase liquid 
chromotography to be 2.25 (Supplemental Figure S1B, Supplemental Table S2) and by 
hydrophobic interaction chromatography to be 2.19 (Supplemental Figure S1C, 
Supplemental Table S3). 
HuMax-TAC and ADCT-301 showed strong binding affinity to CD25-positive human 
anaplastic large cell lymphoma derived cell lines Karpas 299 and Su-DHL-1 (Figure 1B). 
Estimated EC50s were in the sub-nanomolar range and were marginally lower for HuMax-
TAC than ADCT-301 in both lines. Binding saturated at around 1 µg/ml for both cell lines, but 
the MFI was approximately three-fold higher in the Su-DHL-1 compared to the Karpas 299 
cell line reflecting the difference in copy number (Table 1). In contrast, a non-binding ADC 
containing the same drug linker payload showed no binding to either cell line at 30 µg/ml. 
Using soluble CD25 ectodomain, equilibrium dissociation constant (KD) measurements of 
HuMax-TAC or ADCT-301 determined by surface plasmon resonance were 15 pM and 20 
pM, respectively. Representative SPR sensorgrams for HuMax-TAC and ADCT-301 are 
shown in Figure 1C and 1D, respectively.  
Selective cytotoxicity of ADCT-301 in vitro 
The in vitro cytotoxicity of ADCT-301 was determined in a panel of human lymphoma CD25-
expressing (Su-DHL-1, HDLM-2, L540, Karpas 299) and non-expressing (Ramos, HuT-78, 
Daudi) cell lines. These values were derived from graphs shown in Supplemental Figure 
S2A. Additionally, cytotoxicity in myeloid leukemia lines, EoL-1 (CD25-expressing) and KG-1 
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(CD25 non-expressing) was determined. As shown in Table 1, the GI50 values for ADCT-301 
in the CD25-positive lines ranged from 0.04-2.94 ng/ml. GI50 values in the CD25-negative 
lines were > 1,000 ng/ml. The non-binding ADC gave GI50 values > 1,000 ng/ml in both 
antigen expressing and non-expressing lines (Supplemental Figure S2B). No clear 
relationship between GI50 value and mean CD25 copy number was observed for ADCT-301 
in the five CD25-positive cell lines (r=-0.07; p = 0.91). In contrast to the ADC, the naked 
warhead, SG3199, was cytotoxic against all the lines tested and did not discriminate 
between CD25-expressing and non-expressing cells (Table 1). HuMax-TAC antibody up to 
1,000 ng/ml was not cytotoxic in CD25-positive or CD25-negative cell lines (Supplemental 
Figure S2C).  
Following exposure to ADCT-301, reduction of CD25-negative Ramos cell viability was 
shown when co-cultured (50:50) with CD25-expressing Karpas 299 cells, indicating a 
bystander killing effect (Figure 2A upper panel). ADCT-301 at both 1 and 10 ng/ml induced a 
highly significant difference (p ≤ 0.001) in Ramos viability in mono-culture compared to 
Ramos+Karpas 299 co-culture. A significant difference (p ≤ 0.05) between GI50 values for 
Ramos treated for 96h with the medium taken from 48h ADCT-301-treated Karpas 299 and 
Ramos treated for 96h with ADCT-301 in fresh medium was also demonstrated (Figure 2B 
upper panel). In contrast, there was no significant effect on Ramos survival when treated 
with 1 or 10 ng/ml of non-binding ADC (Figure 2A lower panel) or conditioned media taken 
from non-binding ADC-treated Karpas 299 (Figure 2B lower panel).  
ADCT-301 internalization 
CD25-expressing cells exposed to ADCT-301 (1h at 4°C) showed prominent cell surface 
binding (T=0h) (Figure 2C). On incubation at 37°C, ADCT-301 is beginning to be internalized 
by 1h with cell membrane labelling still evident and co-localization with lysosomes observed 
by 4h. In contrast, no cell surface binding is observed with a non-binding ADC at T=0h. For 
Karpas 299, there was a reduction of CD25 molecules on the cell surface, as measured by a 
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reduction in MFI of cells labeled with a FITC-conjugated non-competitive anti-CD25 
antibody, over the first three hours post-treatment. The change in surface CD25 molecules 
after ADCT-301 exposure was significant (p ≤ 0.05) compared to that observed after non-
binding ADC exposure. A return to pre-treatment CD25 MFI occurred by 16h (Figure 2D). In 
addition to a change in CD25 receptor number, the MFI of cells incubated with ADCT-301 
and stained with an AF488-labeled anti-human IgG antibody was reduced over a time 
course up to 4h following incubation at 37°C (Figure 2E).  
DNA interstrand cross-link formation  
DNA interstrand cross-linking was measured using a modification of the single cell gel 
electrophoresis (comet) assay. Representative comet images are shown in Figure 3A. 
Cross-linking was expressed as the percentage decrease in the Olive Tail Moment (OTM) 
compared to control irradiated cells. Following a two-hour exposure of Karpas 299 cells to 20 
ng/ml of ADCT-301, the time course of cross-link formation is shown in Figure 3B. Cross-
links formed after an initial delay, reaching a peak between four and eight hours. In contrast, 
the free warhead at an equimolar equivalent warhead dose reached the peak of cross-linking 
during the two hour exposure. In both cases cross-links persisted over at least 36 hours. The 
non-binding ADC at 20 ng/ml did not show a significant reduction in OTM over the same time 
course. An equivalent experiment in Su-DHL-1 cells, gave the same kinetics of cross-link 
formation resulting in a slightly higher peak (Figure 3C), possibly reflecting the higher CD25 
copy number and sensitivity of this line to ADCT-301.  
At maximum cross-linking (24h) in both Karpas 299 (Figure 3D) and Su-DHL-1 (Figure 3E), 
a correlation between loss of viability and cross-link formation (r = 0.9745 and r = 0.9485, 
respectively; p ≤ 0.05) was established. No evidence of cross-linking after treatment with 1 
µg/ml ADCT-301 could be demonstrated in CD25-negative Daudi cells (Supplemental Figure 
S3). However, cross-linking by naked warhead in CD25-negative Daudi was similar to that in 
CD25-positive cell lines. 
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DNA damage response, cell cycle arrest and apoptosis 
We have previously shown that PBD-induced DNA interstrand cross-links induce a robust, 
but delayed γ- H2AX response (34). In Karpas 299 cells γ-H2AX foci were observed 24h 
after a two-hour exposure to sub-GI50 concentrations of ADCT-301 (Figure 4A). After 
treatment with 60 pg/ml or 1000 pg/ml ADCT-301, γ-H2AX foci increased by 17 or 34 fold 
relative to untreated cells, respectively (p ≤ 0.05 and p ≤ 0.01). In these cells continuous 
exposure to 3 or 10 ng/ml ADCT-301 resulted in a dose-dependent G2/M arrest reaching a 
maximum at 48h as evidenced by a decreased percentage of cells in G0/G1 and an 
increased percentage in G2/M compared to untreated control (Figure 4B). A GI50 warhead 
concentration (15 pM) induced G2/M cell cycle arrest in a similar fashion to a GI50 
concentration of ADCT-301 (3 ng/ml - containing the equivalent of 46 pM of payload in this 
cell line, although this occurred earlier peaking at 24h (Figure 4C). After continuous 
exposure to 10 ng/ml ADCT-301, the peak of the early apoptosis marker annexin-V on the 
cell surface of Karpas 299 cells was observed between 60 and 72h (Figure 4D). Maximal 
loss of viability was at 96h. Non-binding ADC (10 ng/ml) did not induce cell cycle G2/M 
arrest (Figure 4B) or increased Annexin-V and loss of viability (Figure 4D).  
In vivo efficacy of ADCT-301 
In vivo, ADCT-301 demonstrated dose-dependent antitumor activity against both 
subcutaneous and disseminated lymphoma models. In the subcutaneous CD25-expressing 
Karpas 299 xenograft, a single dose of ADCT-301 delayed tumor growth in a dose-
dependent fashion with the 0.6 mg/kg cohort demonstrating 10/10 tumor-free survivors at 
Day 60 (Figure 5A). TTE survival analyses compared to vehicle control were superior at 0.1 
mg/kg (log-rank test p ≤ 0.05) and at 0.2, 0.4 and 0.6 mg/kg (p ≤ 0.001) (Supplemental 
Figure S4A). Similarly a single dose of 0.5 mg/kg ADCT-301 produced 10/10 tumor-free 
survivors maintained at Day 75, whereas a single dose of 0.5 mg/kg Adcetris (targeting 
CD30) only delayed tumor growth and even four 0.5 mg/kg doses (q4d x 4) failed to cure 
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mice (Figure 5B). CD30 expression on Karpas 299 is two to three times higher than CD25 
(inset to Figure 5B). Kaplan Meier analyses showed ADCT-301 significantly superior (p ≤ 
0.01) to Adcetris single dose administration (Supplemental Figure S4B). In a disseminated 
Karpas 299 model, single dose ADCT-301 also showed significant dose-dependent 
extensions of survival in comparison to vehicle control at all four doses tested (p ≤ 0.001) 
(Supplemental Figure S5A). Single-dose ADCT-301 at 0.6 mg/kg showed significant (p ≤ 
0.05) improvement in survival compared to single-dose Adcetris administration 
(Supplemental Figure S5B). In both subcutaneous and disseminated models (0.5 mg/kg and 
0.6 mg/kg, respectively) non-binding ADC failed to show significant tumor regression or 
survival benefit compared to vehicle controls (Figure 5B, Supplemental Figure S4B, 
Supplemental Figure S5A).  In the subcutaneous Su-DHL-1 xenograft, a single dose of 
ADCT-301 delayed tumor growth in a dose-dependent fashion with the 0.6 mg/kg cohort 
demonstrating 6/8 tumor-free survivors at Day 74 (Figure 5C). In contrast, single dose (0.5 
mg/kg) ADCT-301 in disseminated CD25-negative Ramos xenografts failed to show a 
survival benefit (Supplemental Figure S6). In non-tumor bearing SCID mice the maximum 
tolerated dose, as defined by less than 10% weight loss, was 9 mg/kg ADCT-301. The half-
life of naked antibody, HuMax-Tac was 7.3 days. Similarly, the half-life of ADCT-301 by 
analysis of the conjugated antibody with DAR component ≥ 1 was 7.3 days. 
Pharmacodynamic assessment of ADCT-301 in vivo 
In SCID mice with Karpas 299 subcutaneous tumors, a single dose of ADCT-301 was 
administered at 0.2 or 0.6 mg/kg. 24h after treatment, excised tumors showed a dose related 
increase in intensity of staining by an anti-PBD payload antibody and a γ-H2AX antibody 
(Figure 5D). A magnified section of the ADCT-301 0.6 mg/kg anti-PBD payload antibody 
panel indicates that tumour cells demonstrate both membrane and cytosolic staining. 
Reduction in OTM was 23% (0.2 mg/kg) vs 49% (0.6 mg/kg) (p ≤ 0.01) using the comet 
assay (Figure 5E). No cross-linking was observed in peripheral blood lymphocyte samples 
from the same mice (Supplemental Figure S7). The selective targeting of ADCT-301 to 
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CD25-expressing tumor cells and resulting formation of DNA interstrand cross-links and 
associated DNA damage response are therefore confirmed in vivo. 
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Discussion 
ADCs delivering PBD dimer payloads represent a novel mode of action in the ADC arena. 
They exploit a completely different cellular mechanism to the widely used auristatin and 
maytansinoid tubulin inhibitors and a different mode of action to other DNA-interacting 
warheads such as calicheamicin.(27) Several PBD-containing ADCs are now in Phase I 
clinical trials including SGN-33A(27), SGN-70A(35), SC16LD6.5(36) and ADCT-301. In the 
synthesis of ADCT-301, the warhead SG3199 is connected via its N10 position to a 
maleimidocaproyl val-ala dipeptide linker (as in SC16LD6.5). The maleimide then covalently 
and stochastically reacts with a limited number of reduced inter-chain disulphide bonds in 
HuMax-TAC.  In contrast, SGN-33A and SGN-70A are conjugated via a val-ala linker to the 
C2 position on the PBD dimer SGD-1882. Since the N10 position imine is involved in 
covalent binding to DNA, linker attachment at this point produces a pro-drug and an ADC 
payload as well as potentially adding a further level of safety. As a result, attachment at the 
N10 imine requires a self-immolative linker that becomes completely traceless following 
cleavage.  
Binding of ADCT-301 and HuMax-TAC to CD25-positive cell lines (flow cytometry) and to 
soluble CD25 (SPR) was comparable, indicating that conjugation to PBD-linker did not affect 
antigen binding. Our in vitro models show that HuMax-TAC is not itself directly cytotoxic. All 
cell lines studied were sensitive to SG3199 warhead.  The CD25-positive cell line least 
sensitive to ADCT-301 was also least sensitive to SG3199 warhead. In all four CD25-
positive lymphoma cell lines tested picomolar potency to ADCT-301 is demonstrated but 
there was no clear relation between sensitivity to ADCT-301 and CD25 expression level. All 
these cells lines however had high levels of CD25 expression (77,000 to 310,000) and cell 
lines with much lower CD25 expression may be required to determine the threshold for 
cytotoxic sensitivity. An eosinophilic leukemia cell line, EoL-1 with a surface CD25 
expression of 17,000 demonstrated femtomolar in vitro sensitivity to ADCT-301 and free 
SG3199, suggesting that tumor type sensitivity to free warhead varies considerably between 
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tumor types and may predict targeted ADC cytotoxicity independently of CD25 expression 
level above a certain threshold expression level.  
If ADCT-301 is to be efficacious in lymphomas with heterogeneous CD25 expression(2), the 
existence of  bystander toxicity on target-negative tumor cells is important. PBD warhead 
released from the target-positive cell would be expected to be diffusible in contrast to less 
permeable payloads such as MMAF.(37) Initial co-culture experiments of CD25-negative 
Ramos with CD25-positive Karpas 299 resulted in loss of Ramos cells, possibly due to the 
Treg suppressive phenotype of Karpas 299.(38) Therefore, Ramos and Karpas 299 were co-
cultured in the presence of a TGF-β signalling antagonist to ablate the T-reg suppressive 
effect.(39) In both medium transfer and co-culture experiments, Ramos cells were killed by a 
soluble factor released from ADCT-301-treated Karpas 299 cells into the medium. We 
hypothesise that this soluble factor is SG3199 warhead, released by lysosomal cleavage of 
the val-ala dipeptide linker in ADCT-301 and the self-immolative cleavage of the residual 
linker stub on the PBD N10 imine, since we have shown that any transfer of intact ADC 
would be inactive against the CD25-negative Ramos cells. 
Evidence for internalization of ADCT-301 is provided both by the decline of detected ADC on 
the cell surface of Karpas 299 and the reduction in intensity of membrane 
immunofluorescent staining on L-540 cells. Furthermore, a reduction of CD25 surface 
expression over the first three hours after ADCT-301 treatment is evident, following which 
expression returns to pre-treatment levels by 16h. There is no binding competition between 
the two anti-CD25 antibodies used in this latter assay suggesting that the decline in the 
CD25 copy number represents internalization and downmodulation. Immunofluorescent co-
localization images show that processing of ADCT-301 is at least in part lysosomal.  
An important feature of the highly cytotoxic interstrand cross-linking produced by PBD dimer 
warheads is the minimal DNA distortion which may be responsible for a lack of repair of 
these cross-links and their persistence.(40, 41) The time lag between the peak of cross-
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linking by ADCT-301 and by equimolar warhead likely reflects the slower time taken for ADC 
internalization and cellular processing compared with the diffusible active warhead. We 
detected no cross-link repair over 36h. The strong correlation between the reduction in OTM 
and the loss of cell survival indicates that DNA cross-linking is an important mode of action 
of ADCT-301.  
A DNA damage response (increased γ-H2AX foci) is evident in CD25-positive cells 24h after 
a two-hour exposure to ADCT-301 at concentrations as low as 60 pg/ml. This supports 
previous observations that γ-H2AX is highly sensitive to cellular events induced by DNA 
cross-linking agents including PBD dimers.(34, 41) DNA cross-linking leads to G2/M cell 
cycle arrest and apoptotic cell death.(40, 42) We have shown that ADCT-301 caused G2/M 
arrest peaking at 48h and apoptotic cell death. Thus we confirm that DNA cross-linking 
peaked by four to eight hours and was followed by a γ-H2AX response by 24h. G2/M arrest 
ensued at 48h, phosphatidylserine and phosphatidyltyramine exposure at 72h and loss of 
cell viability at 96h.  
The MTD, PK and stability of ADCT-301 was explored in non-tumor bearing SCID mice. 
These mice tolerated ADCT-301 up to 9 mg/kg. Measured half-lives of naked antibody and 
ADCT-301 in mice serum were identical. CD25 is constitutively expressed on Treg and on 
activated cytotoxic T lymphocytes, B lymphocytes (43) macrophages (44, 45) eosinophils 
(46) and basophils (47).  Anti-CD25 immunoconjugates may contribute to the depletion of 
intratumoral CD25-expressing T cells including Tregs as has been demonstrated for 
90Yttrium-labeled daclizumab(18) and LMB-2 (48). Although the safety and efficacy of 
administering anti-CD25 radiommunoconjugates (16-18) and immunotoxins (19, 20) has 
been established in previous Phase I trials, the consequences of prolonged ablation of Tregs 
remains to be determined.  
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Mice xenografted with Karpas 299 and treated with ADCT-301 show remarkable dose-
response improvements in survival. Single-dose ADCT-301 shows superiority to single-dose 
Adcetris administration in TTE statistical analyses despite the three-fold higher cell surface 
target expression for Adcetris and the higher DAR of Adcetris versus ADCT-301.  Another 
CD25-expressing xenografted cell line, Su-DHL-1 showed significant dose-dependent delays 
in tumour growth and tumor-free survival after treatment with ADCT-301. The targeted in 
vivo efficacy of ADCT-301 is illustrated in the lack of efficacy in both non-targeted ADC 
treatment of Karpas 299 xenografts and in ADCT-301 treatment of a CD25-negative Ramos 
model. 
Using a monoclonal anti-PBD antibody against a PBD payload and anti-γ-H2AX staining has 
confirmed the dose dependent delivery of ADC to the tumor xenograft. The comet assay and 
γ-H2AX immunofluorescence have been used as pharmacodynamics assays in previous 
clinical trials of PBD dimer, SG2000 (25, 26) and the comet assay was used to quantitatively 
assess DNA damage in excised tumor samples in the current study. Extrapolating from in 
vivo data, the mean reduction in OTM in 0.6 mg/kg-treated tumor cells compared to the 0.2 
mg/kg cohort, suggests that a threshold level of DNA cross-linking may be required for in 
vivo efficacy. The absence of significant DNA cross-linking in SCID mouse PBMCs (CD25-
negative) supports the CD25-specificity of ADCT-301 in vivo. These comet data thus provide 
a relevant pharmacodynamic assay for use in the current clinical development of PBD-based 
ADCs including ADCT-301. 
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Tables 
Table 1.  CD25-positive and negative cell lines were incubated with increasing 
concentrations of ADCT-301, or free warhead (SG3199) for 96 hours before processing by 
the MTS assay. Data for each cell line are presented as the GI50 i.e. 50% of the net 
tetrazolium reduction product increase in untreated cells. The mean number of CD25 
molecules per cell line was determined by flow cytometric analysis using Qifikit (DAKO). 
Cell line Tumour type 
Mean CD25 
molecules per cell 
surface (thousands) 
GI50 
ADCT-301 
ng/ml (pM) 
SG3199 
(pM) 
Su-DHL-1 ALCL 310 0.74 (4.96) 12.11 
HDLM-2 HL 167 2.94 (19.60) 158.60 
L-540 HL 96 1.11 (7.49) 14.80 
Karpas 
299 ALCL 77 2.56 (17.07) 18.49 
Ramos Burkitt’s < 1 * > 1,000 (> 6,667) 5.83 
Daudi Burkitt’s < 1 * > 1,000 (> 6,667) 18.11 
HuT-78 CTCL < 1 * > 1,000 (> 6,667) 12.98 
EoL-1  AML 17 0.04 (0.26) 0.79 
KG-1 AML < 1 * > 1,000 (> 6,667) γND 
* 1,000 reflects the limits of sensitivity of this assay below which cell lines were considered CD25 
negative. γ not determined 
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Figure Legends 
Figure 1 
A. Structure of ADCT-301 
B. Flow cytometry measurement of median fluorescent intensity showing binding of 
ADCT-301, HuMax-TAC, and non-binding ADC binding to Karpas 299 and Su-DHL-1 
CD25-positive human cell lines. 
C. Biacore® sensogram depicting injections of naked antibody, HuMax-TAC over a 
Biacore CM3 chip which had soluble CD25 ectodomain immobilized onto its surface. 
Arrow indicates the end of the ADC injection and the beginning of the dissociation 
run. 
D. Corresponding sensogram for ADCT-301 
Figure 2 
A. Histograms depicting percentage viable CD25-negative Ramos cells in mono-culture 
(black bar) and Ramos+Karpas 299 (white bar) in co-culture (50:50) treated with 1 or 
10 ng/ml of either ADCT-301 (top) (***  p ≤ 0.001) or non-binding ADC (bottom) for 
96 hours (ns = not significant).  
B. Viability curves showing percentage Ramos viability compared to untreated control 
wells after a 96 hour exposure either to ADC (black square) or to media transferred 
from ADC-treated Karpas 299 (white triangle). The original ADCT-301 concentration 
titration series is plotted in the top panel (p ≤ 0.05) and that of the non-binding ADC 
in the bottom panel (not significant). 
C. Merged immunofluorescence images of CD25-positive L-540  cells treated with 
ADCT-301 (1 µg/ml) for 1 hour, washed and fixed after T=0, 1 or 4 hours in medium 
at 37 °C and stained with labeled anti-human IgG (green), anti-LAMP-1 (red) and 
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Hoechst 33342 (blue) nuclear stain. Yellow indicates co-localization. Non-binding 
ADC-treated L-540 cells are shown at T=0.  
D. Line graph showing the mean CD25 molecules per cell present on the surface of 
ADCT-301 treated (1 µg/ml) Karpas 299 cells over a time course to 16 hours as a 
percentage of the mean CD25 molecules per cell present on untreated Karpas 299 
E. Line graphs depicting median fluorescence of cells incubated at 37°C in medium 
versus cells kept at 4°C in 0.1% sodium azide at 1, 2 and 4 hours after ADCT-301 
treatment.  
 Figure 3 
A. The single cell-gel electrophoresis (comet) assay was carried out on untreated 
irradiated or un-irradiated Karpas 299 and 1 or 15 ng/ml ADCT-301 or non-binding 
ADC -treated irradiated cells, with image panels showing DNA labeled with propidium 
iodide for each treatment condition. 
B. Line graph showing the percentage reduction in OTM compared to untreated control 
in Karpas 299 cells treated with 300 pM naked warhead, 20 ng/ml (133 pM) (ADCT-
301 or non-binding ADC  
C. Percentage reduction in OTM in Su-DHL-1 cells treated with 300 pM naked warhead 
or 20 ng/ml (133 pM) ADCT-301 
D.  Percentage viability and percentage reduction in OTM are plotted versus 
concentration of equivalent warhead in ADCT-301 treated Karpas 299. 
E. The equivalent curves are plotted for ADCT-301 treated Su-DHL-1. 
Figure 4 
A. Image panels depict Karpas 299 cells untreated, or treated with 60 pg/ml or 1 ng/ml 
ADCT-301 and then stained with AF-488-labeled anti-γ-H2AX (first column) or 
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Hoechst 33342 nuclear stain (middle column). The third column shows the image 
overlays in color. Scale bars represent 20 µm. The bar chart (right) shows the mean 
fold increase in foci per cell in three independent experiments at each concentration 
compared to foci per untreated cell. (* = p ≤ 0.05 ** p ≤ 0.01).  
B. Cell histograms of Karpas 299 either untreated, or treated with 10 ng/ml of non-
binding ADC, 3 or 10 ng/ml of ADCT-301 for 48 hours, in each cell cycle phase (G1, 
S or G2/M) as determined by intensity of propidium iodide staining in one 
representative experiment. The bar chart (below) shows the percentage of cells in 
each cell cycle phase in three independent experiments for each of these treatment 
conditions. (* = p ≤ 0.05) 
C.  Bar chart showing mean fold increase of cells in G2 phase compared to untreated 
control for cells treated with 3 ng/ml (20 pM) ADCT-301 or 15 pM naked warhead at 
16, 24 or 48 hours. 
D. Line graph showing percentage of Karpas 299 cells per well with surface Annexin V 
exposure or non-viable cells as indicated by permeability to viability dye over a time 
course (24, 48, 60, 72 and 96 hours) after treatment with 10 ng/ml ADCT-301 or non-
binding ADC. 
Figure 5 
A. In vivo anti-tumor efficacy of ADCT-301 in subcutaneously implanted Karpas 299 
xenograft model. Compared to injection of vehicle (PBS), ADCT-301 administered 
intravenously (i.v.) at a mean tumor volume of 160 mm3 as a single dose at 0.1, 0.2, 
0.4, and 0.6 mg/kg showed dose-dependent anti-tumor activity.  
B. In vivo anti-tumor efficacy of ADCT-301 in comparison to Adcetris and Non-binding 
ADC. Vehicle (PBS), non-binding ADC (DAR 2.1), ADCT-301 (DAR 2.2) or Adcetris 
(DAR ~4) were administered i.v. at a mean Karpas 299 tumor volume of 130 mm3 as 
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single doses at 0.5 mg/kg. Adcetris was also tested q4d x 4 at 0.5 mg/kg. The mean 
number of CD25 and CD30 molecules per Karpas 299 cell as determined by the flow 
cytometric Qifikit (DAKO) is shown in the inset to the graph.  
C. In vivo anti-tumor efficacy of ADCT-301 in subcutaneously implanted Su-DHL-1 
xenograft model. ADCT-301 was administered i.v. at mean tumor volume of 155 mm3 
at single doses of 0.3 mg/kg or 0.6 mg/kg and tumour growth compared to that 
observed after injection of vehicle (PBS). 
D. Representative scans of formalin fixed paraffin embedded Karpas 299 tumor 
sections, obtained from untreated control SCID mice or mice treated with 0.2 and 0.6 
mg/kg ADCT-301 and stained with an anti-PBD linker antibody (top panel) or an anti-
γ-H2AX antibody (bottom panel). Scale bars indicate 100 µm. A magnified area of the 
anti-PBD linker antibody staining of tumors excised from animals dosed at 0.6 mg/kg 
is shown in the inset to this figure.  
E. Histogram depicting mean OTM in irradiated tumor cell suspensions taken from 
Karpas 299 xenograft models untreated or 24 hours after injection with 0.2 mg/kg or 
0.6mg/kg ADCT-301. (** = p ≤ 0.01 *** p ≤ 0.001) 
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